Payment overview · 2025
General Payments
$743.08
28 reported records · 14 companies
Healthcare provider profile · identity verified
David Gu, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · ALHAMBRA, CA · NPI 1225107006
Verified facts
What the public records show
CMS Open Payments records show David Gu, D.O. received $743.08 in general payments during 2025 across 28 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Kerendia, Linzess, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lumigan by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $154.12 | 20.7% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $153.75 | 20.7% | 7 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $99.98 | 13.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $65.36 | 8.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.19 | 7.8% | 3 | 2025 |
| STRATA Skin Sciences, Inc. | Unresolved — no canonical attribution shown | $30.78 | 4.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.54 | 3.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $24.97 | 3.4% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $23.60 | 3.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.56 | 3.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.91 | 3.0% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $21.76 | 2.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.82 | 2.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.74 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $743.08 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $154.12 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $96.41 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $65.36 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $58.19 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $57.34 | 3 | 2025 |
Source payment records
|
|||||
| XTRAC Normalized: xtrac |
Device | STRATA Skin Sciences, Inc. | $30.78 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $28.54 | 1 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 175 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 162 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 236 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 72 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 92 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 32 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 27 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
175 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
92 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
116 | 65 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
162 | 25 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
72 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
236 | 42 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
170 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1118 | 221 |
| Losartan Potassium | Losartan Potassium | 788 | 157 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 781 | 232 |
| Amlodipine Besylate | Amlodipine Besylate | 734 | 131 |
| Metformin Hcl | Metformin Hcl | 459 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 431 | 85 |
| Celecoxib | Celecoxib | 415 | 117 |
| Tamsulosin Hcl | Tamsulosin Hcl | 409 | 95 |
| Omeprazole | Omeprazole | 380 | 107 |
| Vascepa | Icosapent Ethyl | 348 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 345 | 65 |
| Montelukast Sodium | Montelukast Sodium | 334 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 331 | 71 |
| Azithromycin | Azithromycin | 326 | 215 |
| Levothyroxine Sodium | Levothyroxine Sodium | 301 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 292 | 47 |
| Gabapentin | Gabapentin | 289 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 280 | 51 |
| Meloxicam | Meloxicam | 278 | 80 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 248 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 241 | 60 |
| Jardiance | Empagliflozin | 236 | 42 |
| Dutasteride | Dutasteride | 234 | 52 |
| Alendronate Sodium | Alendronate Sodium | 226 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 222 | 70 |
| Azelastine Hcl | Azelastine Hcl | 205 | 48 |
| Memantine Hcl | Memantine Hcl | 199 | 36 |
| Famotidine | Famotidine | 195 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 192 | 74 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 191 | 47 |
| Lidocaine | Lidocaine | 191 | 47 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 189 | 35 |
| Furosemide | Furosemide | 185 | 33 |
| Memantine Hcl Er | Memantine Hcl | 184 | 39 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 180 | 56 |
| Glipizide | Glipizide | 179 | 35 |
| Creon | Lipase/Protease/Amylase | 175 | 29 |
| Eliquis | Apixaban | 170 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 170 | 59 |
| Pioglitazone Hcl | Pioglitazone Hcl | 166 | 23 |
| Farxiga | Dapagliflozin Propanediol | 162 | 25 |
| Baclofen | Baclofen | 158 | 46 |
| Icosapent Ethyl | Icosapent Ethyl | 156 | 45 |
| Simvastatin | Simvastatin | 155 | 23 |
| Pregabalin | Pregabalin | 153 | 41 |
| Allopurinol | Allopurinol | 148 | 25 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 144 | 42 |
| Finasteride | Finasteride | 141 | 24 |
| Januvia | Sitagliptin Phosphate | 141 | 24 |
| Alprazolam | Alprazolam | 136 | 24 |
| Carvedilol | Carvedilol | 135 | 23 |
| Xarelto | Rivaroxaban | 132 | 16 |
| Fluocinonide | Fluocinonide | 131 | 60 |
| Raloxifene Hcl | Raloxifene Hcl | 129 | 32 |
| Atenolol | Atenolol | 123 | 25 |
| Levetiracetam | Levetiracetam | 119 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 17 |
| Prolia | Denosumab | 116 | 65 |
| Mirtazapine | Mirtazapine | 109 | 16 |
| Sertraline Hcl | Sertraline Hcl | 109 | 17 |
| Ammonium Lactate | Ammonium Lactate | 108 | 45 |
| Hydrocortisone | Hydrocortisone | 108 | 33 |
| Metformin Hcl Er | Metformin Hcl | 106 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 105 | 45 |
| Cyclosporine | Cyclosporine | 104 | 25 |
| Donepezil Hcl | Donepezil Hcl | 104 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 102 | 32 |
| Lorazepam | Lorazepam | 100 | 28 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 98 | 23 |
| Potassium Chloride | Potassium Chloride | 97 | 20 |
| Trazodone Hcl | Trazodone Hcl | 97 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 14 |
| Linzess | Linaclotide | 92 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 89 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 87 | 64 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 86 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 80 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 80 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 78 | 13 |
| Benazepril Hcl | Benazepril Hcl | 74 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 74 | 15 |
| Amoxicillin | Amoxicillin | 73 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 73 | 17 |
| Nifedipine Er | Nifedipine | 73 | 13 |
| Kerendia | Finerenone | 72 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 68 | 16 |
| Prednisone | Prednisone | 68 | 47 |
| Ezetimibe | Ezetimibe | 67 | 19 |
| Lactulose | Lactulose | 67 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 34 |
| Spironolactone | Spironolactone | 66 | 12 |
| Ketoconazole | Ketoconazole | 65 | 19 |
| Valsartan | Valsartan | 63 | 13 |
| Calcitriol | Calcitriol | 61 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 60 | suppressed |
| Ozempic | Semaglutide | 59 | suppressed |
| Restasis | Cyclosporine | 59 | suppressed |
| Lisinopril | Lisinopril | 56 | 12 |
| Tradjenta | Linagliptin | 56 | suppressed |
| Temazepam | Temazepam | 55 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 13 |
| Clonazepam | Clonazepam | 50 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 50 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 49 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 49 | 37 |
| Folic Acid | Folic Acid | 48 | 11 |
| Glimepiride | Glimepiride | 48 | suppressed |
| Latanoprost | Latanoprost | 48 | suppressed |
| Levofloxacin | Levofloxacin | 47 | 39 |
| Vemlidy | Tenofovir Alafenamide | 45 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 45 | 11 |
| Meclizine Hcl | Meclizine Hcl | 44 | 23 |
| Midodrine Hcl | Midodrine Hcl | 43 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 41 | 14 |
| Lansoprazole | Lansoprazole | 41 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Nitroglycerin | Nitroglycerin | 40 | 25 |
| Risperidone | Risperidone | 40 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 39 | suppressed |
| Fenofibrate | Fenofibrate | 39 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 39 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 36 | 22 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 36 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 35 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Ranolazine Er | Ranolazine | 35 | suppressed |
| Repaglinide | Repaglinide | 34 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | 13 |
| Glipizide Er | Glipizide | 33 | suppressed |
| Rivastigmine | Rivastigmine | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 33 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 31 |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Multaq | Dronedarone Hcl | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Methimazole | Methimazole | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Febuxostat | Febuxostat | 29 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 28 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | 13 |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Nystatin | Nystatin | 24 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Ciclopirox | Ciclopirox | 22 | 12 |
| Ciclopirox | Ciclopirox Olamine | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Novolin R | Insulin Regular, Human | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | 11 |
| Olanzapine | Olanzapine | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 15 |
| Dexilant | Dexlansoprazole | 19 | suppressed |
| Lumigan | Bimatoprost | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 12 |
| Risedronate Sodium | Risedronate Sodium | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Silodosin | Silodosin | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Ultiguard Safepack-Pen Needle | Pen Needle, Diabetic,disp Unit | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Colchicine | Colchicine | 17 | suppressed |
| Entecavir | Entecavir | 17 | suppressed |
| Epinastine Hcl | Epinastine Hcl | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Minoxidil | Minoxidil | 17 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 16 | 12 |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Procrit | Epoetin Alfa | 15 | suppressed |
| Propylthiouracil | Propylthiouracil | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Travoprost | Travoprost | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 13 | suppressed |
| Benicar | Olmesartan Medoxomil | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 13 | 11 |
| Lovastatin | Lovastatin | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Perphenazine | Perphenazine | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Dermacinrx Lidogel | Lidocaine Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | 11 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 11 | suppressed |
| Edarbi | Azilsartan Medoxomil | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Risedronate Sodium Dr | Risedronate Sodium | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Valproic Acid | Valproic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $743.08 · 28 records | Bayer Healthcare Pharmaceuticals Inc. | BREZTRI, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, JARDIANCE, Kerendia, LINZESS, PANCREAZE, PAXLOVID, TRELEGY ELLIPTA, Tymlos, XTRAC | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error